Magnetic Resonance Spectroscopy in the Monitoring of Multiple Sclerosis

In addition to providing information on tissue structure, magnetic resonance (MR) technology offers the potential to investigate tissue metabolism and function. MR spectroscopy (MRS) offers a wealth of data on the biochemistry of a selected brain tissue volume, which represent potential surrogate markers for the pathology underlying multiple sclerosis (MS). In particular, the N‐acetylaspartate peak in an MR spectrum is a putative marker of neuronal and axonal integrity, and the choline peak appears to reflect cell‐membrane metabolism. On this basis, a diminished N‐acetylaspartate peak is interpreted to represent neuronal/axonal dysfunction or loss, and an elevated choline peak represents heightened cell‐membrane turnover, as seen in demyelination, remyelination, inflammation, or gliosis. Therefore, MRS may provide a unique tool to evaluate the severity of MS, establish a prognosis, follow disease evolution, understand its pathogenesis, and evaluate the efficacy of therapeutic interventions, which complements the information obtained from the various forms of assessment made by conventional MR imaging.

[1]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[2]  J K Udupa,et al.  MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. , 1999, AJNR. American journal of neuroradiology.

[3]  L. Martí-Bonmatí,et al.  Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. , 2004, Brain : a journal of neurology.

[4]  R. Bakshi,et al.  Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients , 1999, Neurology.

[5]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[6]  Ponnada A. Narayana,et al.  Proton magnetic resonance spectroscopy in multiple sclerosis , 1990, Neurology.

[7]  P. Matthews,et al.  The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[8]  Rohit Bakshi,et al.  Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[9]  C. Lucchinetti,et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.

[10]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.

[11]  Nikos Evangelou,et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.

[12]  J. Babb,et al.  Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. , 2002, Radiology.

[13]  J. Coull.  Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology , 1998, Progress in Neurobiology.

[14]  D. Arnold,et al.  The relationship between diffuse axonal damage and fatigue in multiple sclerosis. , 2004, Archives of neurology.

[15]  R. Bakshi,et al.  Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[16]  Oded Gonen,et al.  Diffusely elevated cerebral choline and creatine in relapsing‐remitting multiple sclerosis , 2003, Magnetic resonance in medicine.

[17]  Alireza Minagar,et al.  Gray Matter Involvement in Multiple Sclerosis: A New Window into Pathogenesis , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[18]  P. Matthews,et al.  Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.

[19]  Alan J. Thompson,et al.  Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR , 2002, Journal of Neurology.

[20]  C H Polman,et al.  MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter , 2005, Magnetic resonance in medicine.

[21]  E. Cabanis,et al.  Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.

[22]  U Klose,et al.  Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. , 2001, Brain : a journal of neurology.

[23]  Rohit Bakshi,et al.  The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction , 2005, NeuroImage.

[24]  R. Bakshi,et al.  Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. , 2001, Archives of neurology.

[25]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[26]  Neuronal cell injury precedes brain atrophy in multiple sclerosis , 2004, Neurology.

[27]  C. Elster,et al.  Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-β therapy on absolute metabolite concentrations , 2002, Magnetic Resonance Materials in Physics, Biology and Medicine.

[28]  J S Wolinsky,et al.  Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging , 2001, Multiple sclerosis.

[29]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[30]  Zhengrong Liang,et al.  Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients , 2003, Neurology.

[31]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[32]  Hompson,et al.  A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .

[33]  Daniel Pelletier,et al.  Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. , 2005, Brain : a journal of neurology.

[34]  R I Grossman,et al.  Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing–remitting MS , 2004, Neurology.

[35]  A. Thompson,et al.  Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis , 2002, Multiple sclerosis.

[36]  P. Matthews,et al.  Thalamic neurodegeneration in multiple sclerosis , 2002, Annals of neurology.

[37]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[38]  Frederik Barkhof,et al.  Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. , 2005, Radiology.

[39]  S. Nelson,et al.  MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy , 2003, Journal of neurology, neurosurgery, and psychiatry.

[40]  Frederik Barkhof,et al.  Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. , 2005, AJNR. American journal of neuroradiology.

[41]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[42]  P. Matthews,et al.  Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis , 2003, Journal of Neurology.

[43]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[44]  A. Kendi,et al.  MR spectroscopy of cervical spinal cord in patients with multiple sclerosis , 2004, Neuroradiology.

[45]  J. Babb,et al.  Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. , 2005, Radiology.

[46]  P. Matthews.  Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. , 2001, Journal of neurology.

[47]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[48]  Massimo Filippi,et al.  Magnetic Resonance Imaging Monitoring of Multiple Sclerosis Lesion Evolution , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[49]  Frederik Barkhof,et al.  Assessing treatment effects on axonal loss—evidence from MRI monitored clinical trials , 2004, Journal of Neurology.

[50]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[51]  A. Thompson,et al.  Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. , 2004, Brain : a journal of neurology.

[52]  Antonio Federico,et al.  Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis , 2005, Journal of the Neurological Sciences.

[53]  Rohit Bakshi,et al.  Fatigue associated with multiple sclerosis: diagnosis, impact and management , 2003, Multiple sclerosis.

[54]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[55]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[56]  Sajja B Rao,et al.  Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis , 2004, Multiple sclerosis.

[57]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[58]  Rohit Bakshi,et al.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. , 2005, Archives of neurology.

[59]  R. Poston,et al.  Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis , 1989, Journal of the Neurological Sciences.

[60]  R. Tarducci,et al.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: results of a preliminary study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[61]  Hans Lassmann,et al.  Cortical lesions and brain atrophy in MS , 2005, Journal of the Neurological Sciences.

[62]  Rohit Bakshi,et al.  Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[63]  M. Zaffaroni.  Biological indicators of the neurodegenerative phase of multiple sclerosis , 2003, Neurological Sciences.

[64]  K. Rammohan.  Axonal injury in multiple sclerosis , 2003, Current neurology and neuroscience reports.

[65]  P M Matthews,et al.  Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. , 2000, Archives of neurology.

[66]  J H Simon,et al.  A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.

[67]  A. J. Thompson,et al.  Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis , 2003, Journal of Neurology.

[68]  Hans Lassmann,et al.  Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.

[69]  Robert Zivadinov,et al.  Clinical–Magnetic Resonance Imaging Correlations in Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[70]  Rohit Bakshi,et al.  Multiple Sclerosis Medical Image Analysis and Information Management , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[71]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[72]  Rohit Bakshi,et al.  Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study , 2003, Neuroreport.

[73]  B. Trapp,et al.  N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.

[74]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[75]  R. Bakshi,et al.  T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. , 2002, Archives of neurology.

[76]  Ponnada A Narayana,et al.  Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain , 2002, Current opinion in neurology.

[77]  P. Livrea,et al.  Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study , 2001, Journal of the Neurological Sciences.

[78]  Guillermo Izquierdo,et al.  Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy , 2004, BMC neurology.